Showing 4091-4100 of 6059 results for "".
- Retinoid Foam Wins FDA Approvalhttps://practicaldermatology.com/news/20120514-new_retinoid_foam_wins_fda_approval/2459804/The FDA has ap
- Celotres Earns CE Mark Approval for Wound Healinghttps://practicaldermatology.com/news/20120504-celotres_earns_ce_mark_approval_for_wound_healing/2459808/European regulators have granted CE Mark approval for Celotres™ hydrogel scaffold from Halscion, Inc. The CE Mark approval was based on the results of a prospective, multi-center, randomized, same-patient controlled, European clinical trial evaluati
- Study: AI Model Outperforms Early-Career Physicians in Skin Lesion Diagnosishttps://practicaldermatology.com/news/analysis-ai-model-outperforms-early-career-physicians-in-skin-lesion-diagnosis/2487332/Data from a new study show that a foundational AI model outperformed early career dermatologists in skin lesion diagnosis, but not more experienced dermatologists, when using a dataset designed to reflect real-world clinical scenarios.
- Rubedo Reports Early Clinical Activity for GPX4 Modulator RLS-1496 in Actinic Keratosishttps://practicaldermatology.com/news/rubedo-reports-early-clinical-activity-for-gpx4-modulator-rls-1496-in-actinic-keratosis/2487263/Rubedo Life Sciences announced preliminary findings from a Phase 1b/2a trial evaluating topical RLS-1496 1% cream in adults with actinic keratosis (AK), reporting reductions in lesion counts alongside favorable tolerability data. The interim findings were presented at the RBC Capital Markets Glob
- Analysis: Pediatric Allergic Rhinitis Doubled in Japan Over 40 Yearshttps://practicaldermatology.com/news/analysis-pediatric-allergic-rhinitis-doubled-in-japan-over-40-years/2487238/A 40-year epidemiologic analysis published in the World Allergy Organization Journal showed an increases in allergic rhinitis (AR), allergic conjunctivitis (AC), and Japanese cedar pollinosis (JCP) among school-aged children in western Japan, while rates of atopic dermatitis (AD) and bro
- PanOxyl Portfolio Highlights Accessibility and Long-Term Acne Management During Virtual Desksidehttps://practicaldermatology.com/news/panoxyl-portfolio-highlights-accessibility-and-long-term-acne-management-during-virtual-deskside/2487257/Acne management requires a broader approach than simply targeting active breakouts, according to speakers during a virtual media deskside hosted by Revance. The discussion focused on over-the-counter acne management strategies with the PanOxyl brand as well as procedural options for acne scar tre
- Systematic Review Highlights Comparative Outcomes Across Molluscum Contagiosum Therapieshttps://practicaldermatology.com/news/systematic-review-highlights-comparative-outcomes-across-molluscum-contagiosum-therapies/2487169/A new systematic review evaluating treatments for molluscum contagiosum (MC) found that curettage, potassium hydroxide (KOH), autoinoculation, and podophyllotoxin demonstrated some of the highest lesion clearance rates among currently available therapies, while ne
- Isotretinoin Use in Adolescence Not Linked to Reduced Adult Height: Analysishttps://practicaldermatology.com/news/isotretinoin-use-in-adolescence-not-linked-to-reduced-adult-height-analysis/2487168/Concerns that isotretinoin therapy during adolescence could impair skeletal growth were not supported by findings from a large nationwide Danish study published in
- From SCALE 2026: Practical Strategies for Treating GLP-1–Related Aesthetic Changeshttps://practicaldermatology.com/news/from-scale-2026-practical-strategies-for-treating-glp-1related-aesthetic-changes/2487118/At the 2026 Music City SCALE meeting, Terrence Keaney, MD, discussed how dermatologists can proactively address facial aging, skin laxity, hair loss, and muscle loss associated with GLP-1–mediated weight reduction, outlining a practical framework for managing some of the aesthetic issues related
- Measure Up Data Support Long-Term Laboratory Safety With Upadacitinib in Atopic Dermatitishttps://practicaldermatology.com/news/measure-up-data-support-long-term-laboratory-safety-with-upadacitinib-in-atopic-dermatitis/2487114/Most laboratory parameters remained within normal limits through 140 weeks of upadacitinib treatment in adolescents and adults with moderate-to-severe atopic dermatitis (AD), according to findings presented at the 2026 Society for Investigative Dermatology Annual